BUDGET IMPACT AND COST-CONSEQUENCE ANALYSIS OF ADOPTING DENECIMIG VERSUSEMICIZUMAB FOR THE TREATMENT OF HAEMOPHILIA A IN SAUDI ARABIA: A PUBLIC PAYER PERSPECTIVE
Author(s)
Yasser Albarakah, BSc, MSc, PhD1, YOUSIF S. ALAKEEL, MPH, PharmD2, Shaima Khader, MSc3, Muhannad Alharbi, MSc3.
1Ministry of Defence Health Services, Riyadh, Saudi Arabia, 2Ministry of the National Guard-Health Affairs, Riyadh, Saudi Arabia, 3HEPA Solutions, Riyadh, Saudi Arabia.
1Ministry of Defence Health Services, Riyadh, Saudi Arabia, 2Ministry of the National Guard-Health Affairs, Riyadh, Saudi Arabia, 3HEPA Solutions, Riyadh, Saudi Arabia.
OBJECTIVES: Haemophilia A imposes substantial healthcare burden in Saudi Arabia; locally, with inhibitors developing in 29.3% of affected patients with haemophilia A. Denecimig, a novel factor VIIIa mimetic bispecific antibody, demonstrates superior bleed prevention versus emicizumab. This study estimates the 5-year budget impact of adopting Denecimig for haemophilia A prophylaxis from the Saudi public payer perspective.
METHODS: A prevalence-based cost-calculator model compared Denecimig with emicizumab over a 5-year period (2025-2029). The eligible population was 1,404 patients (2025), derived from World Federation of Hemophilia 2023 data adjusted for Saudi demographics with 4.70% annual growth. Costs included drug acquisition based on Saudi Food and Drug Authority (SFDA 2026) Cost, Insurance and Freight (CIF) prices and medical resource utilization costs based on annualized bleeding rate differences. Denecimig market uptake was assumed to increase from 10% in Year 1, to 40% by Year 4. Sensitivity analyses were performed.
RESULTS: Annual drug costs per patient were: ≥45 kg: Saudi Riyal (SAR) 1.697 million (Denecimig) vs SAR 1.686 million (emicizumab); 15-45 kg: SAR 737K vs SAR 862K; <15 kg: SAR 306K vs SAR 287K. Medical resource utilization costs of Denecimig: only 5.0% of patients experienced ongoing bleeds (annualized rate: 0.20) vs 43.9% on emicizumab (rate: 2.40). The 5-year net budget impact: Savings are concentrated in 15-45 kg:
SAR 341 million (
24.29%); ≥45 kg: −SAR 106 million (3.87%); <15 kg: +SAR 18 million (+4.01%). Combined projected savings for patients ≥15 kg totaled approximately SAR 447 million, driven primarily by reduced bleeding‑related healthcare utilization.
CONCLUSIONS: Adopting Denecimig for patients with haemophilia A weighing ≥15 kg generates is projected to yield substantial savings for Saudi public payers, primarily driven by clinical superiority in lowering bleeding rates. These projected savings provide Saudi-specific economic evidence supporting Denecimig as a cost-effective prophylactic option that aligns with national cost-containment initiatives and value-based healthcare priorities.
METHODS: A prevalence-based cost-calculator model compared Denecimig with emicizumab over a 5-year period (2025-2029). The eligible population was 1,404 patients (2025), derived from World Federation of Hemophilia 2023 data adjusted for Saudi demographics with 4.70% annual growth. Costs included drug acquisition based on Saudi Food and Drug Authority (SFDA 2026) Cost, Insurance and Freight (CIF) prices and medical resource utilization costs based on annualized bleeding rate differences. Denecimig market uptake was assumed to increase from 10% in Year 1, to 40% by Year 4. Sensitivity analyses were performed.
RESULTS: Annual drug costs per patient were: ≥45 kg: Saudi Riyal (SAR) 1.697 million (Denecimig) vs SAR 1.686 million (emicizumab); 15-45 kg: SAR 737K vs SAR 862K; <15 kg: SAR 306K vs SAR 287K. Medical resource utilization costs of Denecimig: only 5.0% of patients experienced ongoing bleeds (annualized rate: 0.20) vs 43.9% on emicizumab (rate: 2.40). The 5-year net budget impact: Savings are concentrated in 15-45 kg:
SAR 341 million (24.29%); ≥45 kg: −SAR 106 million (3.87%); <15 kg: +SAR 18 million (+4.01%). Combined projected savings for patients ≥15 kg totaled approximately SAR 447 million, driven primarily by reduced bleeding‑related healthcare utilization.CONCLUSIONS: Adopting Denecimig for patients with haemophilia A weighing ≥15 kg generates is projected to yield substantial savings for Saudi public payers, primarily driven by clinical superiority in lowering bleeding rates. These projected savings provide Saudi-specific economic evidence supporting Denecimig as a cost-effective prophylactic option that aligns with national cost-containment initiatives and value-based healthcare priorities.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE588
Topic
Economic Evaluation, Health Policy & Regulatory, Health Technology Assessment
Topic Subcategory
Budget Impact Analysis
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)